The press releases are available in Swedish when no translation exists.
Kista, August 14, 2018. Severn Healthcare Technologies Ltd. ("Severn") and Chordate Medical Holding AB (publ) have signed an exclusive distribution agreement for Chordate's products in UK and Ireland through the subsidiary Chordate Medical AB ("Chordate"). Severn is one of UK's fastest-growing medical technology distributors, with focus on the Ear-Nose-Throat ("ENT") Market.
"We have previously communicated that we will initially target the Nordic, UK and the Middle East, which are mature markets. It is gratifying that we now can increase presence in UK and Ireland together with a strong company like the Severn. For a long time, Chordate has focused on UK, including through our major international rhinitis study where three British university hospitals are involved. However, we see that the marketing efforts needs to be considerably more aggressive. With Severn as a partner, we would gain access to experienced persons from a strong ENT company, which we believe will enable us to reach Chordate's full potential in the UK and Irish markets, "says Anders Weilandt, CEO of Chordate.
Transition to Severn will take place in the third quarter of 2018.
For more information, please contact:Anders Weilandt, CEOanders.email@example.comPhone: +46 (0) 733 87 42 77
Information: This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided through the contact of the above contact person for publication on August 14, 2018 at. 08:30 CET.
TO THE EDITORSAbout ChordateChordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE- marked a new treatment method for chronic nasal congestion through nerve stimulation. The company sells its product system including treatments through its own sales organization as well as distributors to clinics and hospitals, which in turn treat patients. Read more at www.chordate.com. Mangold Fondkommission AB, tel. +46 8 5030 1550, is the company's mentor and liquidity guarantee at NGM Nordic MTF.
Press releases and reports via E-mail.
We are a Swedish medical technology company listed on NGM Nordic SME.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.